Azzolini A, Guffanti E, Ronzitti M, Tantalo L, Colantoni A, Pizzorni C
Professorial Department of Medical Pathology, University of Genova, Italy.
Cardiology. 1990;77 Suppl 5:89-95. doi: 10.1159/000174702.
This double-blind, randomized, multicenter clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12-week treatment period. Ibopamine produced a statistically significant increase in exercise tolerance and reduction in fatigue during effort compared to placebo. A trend towards decreased requirement of concomitant diuretic therapy was noted in the ibopamine-treated group. Ibopamine was well tolerated throughout the study. This study indicated that ibopamine is an effective and safe agent as monotherapy in the treatment of mild chronic heart failure in elderly patients.
这项双盲、随机、多中心临床研究评估了100毫克甲磺酸苯异丙胺每日三次单药治疗与安慰剂相比，在12周治疗期内对52例60岁以上轻度慢性心力衰竭患者的疗效和安全性。与安慰剂相比，甲磺酸苯异丙胺在运动耐力方面产生了具有统计学意义的增加，并且在运动时疲劳减轻。在接受甲磺酸苯异丙胺治疗的组中，观察到伴随利尿剂治疗需求减少的趋势。在整个研究过程中，甲磺酸苯异丙胺耐受性良好。这项研究表明，甲磺酸苯异丙胺作为单药治疗老年患者轻度慢性心力衰竭是一种有效且安全的药物。
